CN100334207C - Preparation method of aspergillus flavus urate oxidase - Google Patents
Preparation method of aspergillus flavus urate oxidase Download PDFInfo
- Publication number
- CN100334207C CN100334207C CNB2004100179484A CN200410017948A CN100334207C CN 100334207 C CN100334207 C CN 100334207C CN B2004100179484 A CNB2004100179484 A CN B2004100179484A CN 200410017948 A CN200410017948 A CN 200410017948A CN 100334207 C CN100334207 C CN 100334207C
- Authority
- CN
- China
- Prior art keywords
- aspergillus flavus
- preparation
- flavus uricoxidase
- uricoxidase
- pet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 101000767281 Aspergillus flavus Uricase Proteins 0.000 title abstract 3
- 241000228197 Aspergillus flavus Species 0.000 claims abstract description 38
- 241000894006 Bacteria Species 0.000 claims abstract description 27
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 26
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 15
- 239000013604 expression vector Substances 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 10
- 239000013612 plasmid Substances 0.000 claims abstract description 10
- 238000012216 screening Methods 0.000 claims abstract description 8
- 241000588724 Escherichia coli Species 0.000 claims abstract description 7
- 230000001939 inductive effect Effects 0.000 claims abstract description 3
- 102000004190 Enzymes Human genes 0.000 claims description 19
- 108090000790 Enzymes Proteins 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 230000004927 fusion Effects 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 8
- 239000002299 complementary DNA Substances 0.000 claims description 7
- 108091008146 restriction endonucleases Proteins 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 6
- 230000002209 hydrophobic effect Effects 0.000 claims description 5
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000004255 ion exchange chromatography Methods 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 102100029727 Enteropeptidase Human genes 0.000 claims description 2
- 108010013369 Enteropeptidase Proteins 0.000 claims description 2
- 238000001042 affinity chromatography Methods 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims 1
- 238000000746 purification Methods 0.000 abstract description 7
- 238000012258 culturing Methods 0.000 abstract description 2
- 238000004153 renaturation Methods 0.000 abstract description 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 238000001976 enzyme digestion Methods 0.000 abstract 1
- 230000001131 transforming effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 28
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 27
- 229940116269 uric acid Drugs 0.000 description 27
- 229940088598 enzyme Drugs 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 8
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 201000001431 Hyperuricemia Diseases 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940075420 xanthine Drugs 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 201000005569 Gout Diseases 0.000 description 4
- 238000013016 damping Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 108010092464 Urate Oxidase Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000004144 purine metabolism Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000000516 activation analysis Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- NUCLJNSWZCHRKL-UHFFFAOYSA-N allantoic acid Chemical compound NC(=O)NC(C(O)=O)NC(N)=O NUCLJNSWZCHRKL-UHFFFAOYSA-N 0.000 description 2
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- ZSSKCFBQOHVANO-UHFFFAOYSA-N 7,9-dihydro-3h-purine-2,6,8-trione;sodium;hydrate Chemical compound O.[Na].N1C(=O)NC(=O)C2=C1NC(=O)N2 ZSSKCFBQOHVANO-UHFFFAOYSA-N 0.000 description 1
- 102000006673 Allantoicase Human genes 0.000 description 1
- 108010049381 Allantoicase Proteins 0.000 description 1
- 108010007828 Allantoinase Proteins 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000235646 Cyberlindnera jadinii Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001556090 Nilaparvata Species 0.000 description 1
- 101710157860 Oxydoreductase Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010045170 Tumour lysis syndrome Diseases 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- FPVGTPBMTFTMRT-NSKUCRDLSA-L fast yellow Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(N)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 FPVGTPBMTFTMRT-NSKUCRDLSA-L 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 235000013928 guanylic acid Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 208000010380 tumor lysis syndrome Diseases 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 230000001751 uricolytic effect Effects 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts
Landscapes
- Enzymes And Modification Thereof (AREA)
Abstract
Description
?001 ?061 ?121 ?181 ?241 ?301 ?361 ?421 ?481 ?541 ?601 ?661 ?721 ?781 ?841 ?901 | ?gag catatgt?ccgcggtTaa?agcagcccgc?tacggcaaGg?acaacgttcg?cgtgtacaag ?gttcacaaag?acgagaagac?cggtgtccag?acggtgtacg?agatgaccgt?ctgtgtgctt ?ctggagggtg?agattgagac?cAGttacacc?aaggccgaca?acagcgtcat?tgtcgcaacc ?gacAGcatta?agaacaccat?ttacatcacc?gccaagcaga?accccgttac?tcctcccgag ?ctgttcggct?ccatcctggg?cacacacttc?attgagaagt?acaaccacat?ccatgccgct ?cacgtcaaca?ttgtctgcca?ccgctggacc?cggatggaca?ttgacggcaa?gccacacccG ?cacAGcttca?tccgcgacag?cgaggagaag?cggaatgtgc?aggtggacgt?ggtcgagggc ?aagggcatcg?atatcaagtc?gtctctgtcc?ggcctgaccg?tgctgaagag?caccaactcg ?cagttctggg?gcttcctgcg?tgacgagtac?accacactta?aggagacctg?ggaccgtatc ?ctgagcaccg?acgtcgatgc?cacttggcag?tggaagaatt?tcagtggact?ccaggaggtc ?cgctcgcacg?tgcctaagtt?cgatgctacc?tgggccactg?ctcgcgaggt?cactctgaag ?acttttgctg?aagataacag?tgccagcgtg?caggccacta?tgtacaagat?ggcagagcaa ?atcctggcgc?gccagcagct?gatcgagact?gtcgagtact?cgttgcctaa?caagcactat ?ttcgaaatcg?acctgagctg?gcacaagggc?ctccaaaaca?ccggcaagaa?cgccgaggtc ?ttcgctcctc?agtcggaccc?Gaacggtctg?atcaagtgta?ccgtcggccg?gtcctctctg ?aagtctaaat?tgTAACTGA g?gatccAga (restriction enzyme site of line place) for introducing |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100179484A CN100334207C (en) | 2004-04-27 | 2004-04-27 | Preparation method of aspergillus flavus urate oxidase |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100179484A CN100334207C (en) | 2004-04-27 | 2004-04-27 | Preparation method of aspergillus flavus urate oxidase |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1690197A CN1690197A (en) | 2005-11-02 |
CN100334207C true CN100334207C (en) | 2007-08-29 |
Family
ID=35345955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100179484A Expired - Lifetime CN100334207C (en) | 2004-04-27 | 2004-04-27 | Preparation method of aspergillus flavus urate oxidase |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100334207C (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100406560C (en) * | 2006-03-15 | 2008-07-30 | 中国人民解放军军事医学科学院微生物流行病研究所 | Method for expression of Aspergillus flavus urate oxidase and the special gene thereof |
CN101255440B (en) * | 2008-03-12 | 2012-02-01 | 中国科学院微生物研究所 | Recombinant polymorphism hansenula as well as special recombinant expression vectors and uses thereof |
CN101402688B (en) * | 2008-11-18 | 2011-04-20 | 中国人民解放军军事医学科学院生物工程研究所 | Fusion protein, encoding gene and uses thereof |
CN101928704A (en) * | 2010-03-04 | 2010-12-29 | 杭州北斗生物技术有限公司 | Polyethylene glycol modifier of aspergillus flavus urate oxidase and preparation method thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1322243A (en) * | 1998-08-06 | 2001-11-14 | 杜克大学 | Urate oxidase |
-
2004
- 2004-04-27 CN CNB2004100179484A patent/CN100334207C/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1322243A (en) * | 1998-08-06 | 2001-11-14 | 杜克大学 | Urate oxidase |
Non-Patent Citations (1)
Title |
---|
尿酸氧化酶基因的克隆、表达及其产物的应用 朱献军等人,生物工程学报,第17卷第1期 2001 * |
Also Published As
Publication number | Publication date |
---|---|
CN1690197A (en) | 2005-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102191291B (en) | Method for producing L-ornithine hydrochloride by genetic engineering bacteria | |
CN102250848B (en) | Method for purifying recombinant aspergillus flavus uricase expressed by bacillus coli | |
CN102618552A (en) | Productive technology of recombined exenatide | |
CN101302526A (en) | Recombinant soluble streptococcus hemolyticus haemolysin O gene, recombinant protein and preparation thereof | |
CN106939315B (en) | Preparation method and application of oxalate decarboxylase | |
CN100334207C (en) | Preparation method of aspergillus flavus urate oxidase | |
CN104694524A (en) | Method for preparing glutamic acid decarboxylase mutant by utilizing ramachandran map information and mutant thereof | |
CN107955806B (en) | Preparation method and application of superoxide dismutase Cu, Zn SOD (superoxide dismutase) from deep-sea cucumber | |
CN102234624B (en) | Genetic engineering strain for expression and generation of bacillus subtilis arginase, and constructing method thereof | |
CN103966191B (en) | The tryptic preparation method of a kind of recombinant bovine source property | |
CN100406560C (en) | Method for expression of Aspergillus flavus urate oxidase and the special gene thereof | |
CN103468660A (en) | High-activity neutral phytase mutant, and gene and use thereof | |
CN103031295B (en) | Cordyceps cytidine deaminase, coding gene and application thereof | |
CN106480074B (en) | A kind of swamp eel aldehyde ketone reductase gene and its vivoexpression method | |
CN104946606A (en) | Genetic engineering transformed thermal-resistant adverse-resistant SOD as well as encoding gene and application thereof | |
CN101638640B (en) | Glucose-6-phosphoric acid dehydrogenase and nucleotide sequence, recombinant vector, recombinant host cell and kit thereof | |
CN103031285A (en) | Cordyceps Chinese Hirsutella uridine-cytidine kinase, coding gene and application thereof | |
CN108840934B (en) | Recombinant sheep long-acting interferon tau, fusion protein for preparing long-acting interferon tau and preparation method of fusion protein | |
CN114350642B (en) | Method for improving yield of xylanase and its mutant and application | |
CN103805622A (en) | Novel preparation process of genetic engineering IFN (interferon) alpha-2b fusion protein | |
CN104911155B (en) | Using the heat-resistant of genetic engineering transformation against SOD and its encoding gene and application | |
CN103031287B (en) | Cordyceps Chinese Hirsutella nucleoside diphosphokinase, coding gene and application thereof | |
CN109022471A (en) | Produce the escherichia expression system of oxalate oxidase, the production method and its application of oxalate oxidase | |
CN101168738A (en) | Expression of recombined bovine pancreas ribonucleic acid hydrolase A and purifying method thereof | |
CN107236720A (en) | Heat resistant fibre disaccharide-hydrolysing enzymes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: JILIN XIUZHENG PHARMACEUTICAL NEW MEDICINE DEVELOP Free format text: FORMER OWNER: HANGZHOU BIODOOR BIOTECHNOLOGY CO., LTD. Effective date: 20100902 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 310012 NO.28, WENER STREET, HANGZHOU CITY, ZHEJIANG PROVINCE TO: 130012 NO.2426, QIANJIN AVENUE, CHANGCHUN CITY, JILIN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100902 Address after: 130012 No. 2426 Qianjin Street, Jilin, Changchun Patentee after: JILIN XIUZHENG PHARMACEUTICAL NEW MEDICINE DEVELOPMENT Co.,Ltd. Address before: 310012 No. two 28 street, Hangzhou, Zhejiang Patentee before: HANGZHOU BIODOOR BIOTECHNOLOGY Co.,Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: CHANGCHUN SHENGJINNUO BIOLOGICAL PHARMACEUTICAL CO Free format text: FORMER OWNER: JILIN XIUZHENG PHARMACEUTICAL NEW MEDICINE DEVELOPMENT CO., LTD. Effective date: 20150814 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150814 Address after: 130103 No. 1239 Shunda Road, hi tech Development Zone, Jilin, Changchun Patentee after: CHANGCHUN SHENGJINNUO BIOLOGICAL PHARMACEUTICAL Co.,Ltd. Address before: 130012 No. 2426 Qianjin Street, Jilin, Changchun Patentee before: JILIN XIUZHENG PHARMACEUTICAL NEW MEDICINE DEVELOPMENT Co.,Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20070829 |
|
CX01 | Expiry of patent term |